Search Results
Nov 20, 2025, 14:57 ET Caída de precios, aumento de costes y escasez: conclusiones de un estudio de Viatris y Medicines for Europe
Viatris Inc. (Nasdaq: VTRS), una compañía global de atención médica, junto con Medicines for Europe – la voz de las industrias de medicamentos genéricos, biosimilares y de valor
More news about: Viatris Inc.
Nov 20, 2025, 14:49 ET Европейское исследование показывает падение цен, рост затрат и дефицит -- результаты независимого исследования, представленного Viatris и Medicines for Europe на Всемирной неделе осведомленности об УПП
Viatris Inc.(Nasdaq: VTRS) совместно с организацией Medicines for Europe, выступающей за воспроизведенные, биоаналогичные и улучшенные лекарства в Европе, представили результаты
More news about: Viatris Inc.
Nov 19, 2025, 19:28 ET Európska štúdia zisťuje klesajúce ceny, rastúce náklady a nedostatky - Viatris a Medicines for Europe prezentujú nezávislú štúdiu počas Svetového týždňa povedomia o antimikrobiálnej rezistencii (AMR)
Viatris Inc. (Nasdaq: VTRS), globálna zdravotnícka spoločnosť, spolu s asociáciou Medicines for Europe – hlasom odvetvia generických, biosimilárnych a liekov s pridanou hodnotou
More news about: Viatris Inc.
Nov 19, 2025, 19:21 ET Une étude européenne révèle une baisse des prix, une augmentation des coûts et des pénuries - conclusions d'une étude indépendante présentées par Viatris et Medicines for Europe lors de la Semaine mondiale de sensibilisation à la résistance aux antimicrobiens.
Viatris Inc. (Nasdaq : VTRS), une entreprise mondiale du secteur de la santé, et Medicines for Europe – porte-parole des industries des médicaments génériques, biosimilaires et
More news about: Viatris Inc.
Nov 19, 2025, 19:14 ET Europäische Studie zeigt sinkende Preise, steigende Kosten und Engpässe - Ergebnisse einer unabhängigen Studie, die während der World AMR Awareness Week von Viatris und Medicines for Europe vorgestellt wurden
Viatris Inc. (Nasdaq: VTRS), ein globales Gesundheitsunternehmen, und Medicines for Europe – die Stimme der Generika-, Biosimilar- und Mehrwertmedikamentenindustrie in Europa –
More news about: Viatris Inc.
Nov 19, 2025, 19:06 ET Europejskie badanie pokazuje spadające ceny, rosnące koszty i niedobory - wyniki niezależnego badania przedstawione podczas Światowego Tygodnia Wiedzy o Antybiotykach przez firmę Viatris i organizację Medicines for Europe
Viatris Inc. (Nasdaq: VTRS), globalna firma z branży opieki zdrowotnej, wraz z organizacją Medicines for Europe - reprezentującą producentów leków generycznych, biopodobnych i
More news about: Viatris Inc.
Nov 19, 2025, 18:02 ET Evropská studie ukazuje klesající ceny, rostoucí náklady a nedostatek - výsledky nezávislé studie představené během Světového týdne povědomí o antimikrobiální rezistenci společnostmi Viatris a Medicines for Europe
Viatris Inc. (Nasdaq: VTRS) společně s Medicines for Europe – hlasem odvětví generických, biosimilárních a přidanou hodnotou obohacených léčivých přípravků v Evropě – výsledky
More news about: Viatris Inc.
Nov 19, 2025, 03:00 ET European study shows falling prices, rising costs and shortages - findings from independent study presented during World AMR Awareness Week by Viatris and Medicines for Europe
Viatris Inc. (Nasdaq: VTRS), a global healthcare company, with Medicines for Europe – the voice of the generic, biosimilar, and value-added medicines industries in Europe – present
More news about: Viatris Inc.
Nov 13, 2025, 08:00 ET Viatris Recognized as One of the Fortune World's Best Workplaces™ in 2025
Viatris Inc. (Nasdaq: VTRS) today announced that it has been recognized as one of the
More news about: Viatris Inc.
Nov 06, 2025, 06:59 ET Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance
Viatris Inc. (Nasdaq: VTRS) today reported strong third quarter 2025 financial results and updated full-year financial guidance.
More news about: Viatris Inc.
Nov 04, 2025, 06:59 ET Viatris Announces Quarterly Dividend
Viatris Inc. (Nasdaq: VTRS) today announced that on November 3, 2025, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share
More news about: Viatris Inc.
Oct 15, 2025, 16:30 ET Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region
Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it has acquired Aculys Pharma, Inc., a clinical stage biopharmaceutical company focused on commercializing
More news about: Viatris Inc.
Oct 13, 2025, 06:59 ET Viatris to Participate in Upcoming Investor Conferences
Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will participate in two upcoming healthcare conferences in November 2025.
More news about: Viatris Inc.
Oct 08, 2025, 11:00 ET Viatris Named to Forbes' Annual List of the World's Best Employers for the Fifth Year in a Row
Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that it has been named to
More news about: Viatris Inc.
Oct 01, 2025, 09:00 ET Viatris to Report Third Quarter 2025 Financial Results on November 6, 2025
Viatris Inc. (Nasdaq: VTRS) will report third quarter 2025 financial results on Thursday, November 6, 2025. Company executives will host a webcast at 8:30 a.m. ET on the same date
More news about: Viatris Inc.